Alimera Sciences Inc. (ALIM)

0.38
0.01 3.50
NASDAQ : Health Technology
Prev Close 0.39
Open 0.39
Day Low/High 0.37 / 0.39
52 Wk Low/High 0.32 / 1.21
Volume 28.66K
Avg Volume 304.00K
Exchange NASDAQ
Shares Outstanding 71.01M
Market Cap 28.40M
EPS -0.20
P/E Ratio 1.29
Div & Yield N.A. (N.A)

Latest News

Alimera Sciences Announces Clinical Data Featuring The Benefits Of ILUVIEN® To Be Presented At The American Academy Of Ophthalmology Annual Meeting

Alimera Sciences Announces Clinical Data Featuring The Benefits Of ILUVIEN® To Be Presented At The American Academy Of Ophthalmology Annual Meeting

Data highlight ILUVIEN's advantages as the only therapy that consistently treats diabetic macular edema (DME) for up to 3 years

Alimera Announces Expansion Of Agreement With Distribution Partner Horus Pharma To Include Marketing ILUVIEN® In Benelux Countries

Alimera Announces Expansion Of Agreement With Distribution Partner Horus Pharma To Include Marketing ILUVIEN® In Benelux Countries

Following successful launch of ILUVIEN in France, Horus will bring the product to patients in Belgium, the Netherlands, and Luxembourg

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARES, HPR, IDCC, INS, IOR, RXN, TCI, TEO, TSU, VST, WMK Downgrades: ALIM, BBGI, CAG, CBM, CNDT, DEI, FNJN, NNBR, PENN Initiations: LOMA, NVMM Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AES, ALIM, APPS, EXAS, INVH, LBRDA, LBRDK, LLY, TLK Downgrades: CTT, DRH, HA, MTDR, ORIT, RNG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy

TheStreet Quant Rating: D- (Sell)